'More balanced' appeals might make NICE nicer, says industry
This article was originally published in Scrip
Executive Summary
The panel that hears appeals against guidance from NICE, the health technology appraisal body for England and Wales, will become more independent from the institute, according to England's Department of Health. The move gives companies the chance of more "balanced" hearing, says the Association of the British Pharmaceutical Industry. However, it does not make it any easier for them to actually get a hearing in the first place as the department has no plans to widen the grounds for appeal.